Lifecore Biomedical, Inc. — Form 8-K Summary
Reporting event: September 27, 2026. The filing reports a proposed acquisition, not quarterly or annual operating results. Lifecore Biomedical, Inc. is to become a wholly owned subsidiary of Lifecore Inc., an affiliate of Webster Equity Partners, if the transaction closes.
Transaction terms and key financial details
- Common stock consideration: $6.28 per share in cash, without interest, plus one contingent value right (CVR) per share. Series A preferred stock receives its defined Conversion Amount in cash plus CVRs based on the shares into which it is convertible.
- Equity awards: Options accelerate; in-the-money options receive cash based on the difference between $6.28 and their exercise price, plus CVRs. Options with exercise prices at or above $6.28 are canceled without consideration. RSUs and PSUs are generally converted into the applicable merger consideration, subject to the agreement’s terms and tax withholding.
- CVR milestones: Potential payments are $30 million for the 2028 revenue milestone, $45 million for the 2029 revenue milestone, and $85 million for the 2030 milestone of at least $120 million in consolidated EBITDA. The 2028 and 2029 milestones require specified non-Alcon revenue levels and either specified Alcon revenue or aggregate revenue levels. Partial payments may apply under specified conditions; the 2028 payment also has a 2029 catch-up provision. Specified litigation may result in adjustments of up to $10 million. CVRs are non-tradeable except in limited circumstances, and may pay nothing.
- Financing commitments: Parent has $400 million in equity commitments, plus debt commitments of $115 million in term loans and a $30 million revolving facility from two lenders, and a $35 million term loan from Alcon. The filing says committed financing is sufficient in aggregate for the purchase price and related expenses, and closing is not subject to a financing condition. Debt commitments remain subject to customary conditions.
- Termination fees: The agreement specifies a $7,468,287 go-shop fee, a $9,957,716 company termination fee, and a $16,181,288 reverse termination fee. Fees apply only in specified circumstances.
The filing does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures, nor a clear standalone operating forecast. The milestone thresholds are contingent CVR terms, not management guidance.
Material changes and transaction process
- The board and its Transaction Committee unanimously approved the merger agreement and recommended that stockholders adopt it. The company must seek stockholder approval at a special meeting.
- Closing requires stockholder approval, HSR waiting-period expiration or termination, other required governmental approvals, no prohibiting legal restraint, continued effectiveness of specified Alcon agreements, and satisfaction of other customary conditions. Parent and Merger Sub also have a no-continuing-material-adverse-effect closing condition.
- The initial termination date is June 27, 2027, automatically extending to September 27, 2027 if HSR clearance is the only unsatisfied closing condition and the other specified conditions are met.
- Lifecore may solicit competing proposals during a 30-day go-shop period after public announcement. Thereafter, customary no-shop restrictions apply, subject to exceptions and the agreement’s superior-proposal process.
- Wynnefield- and Legion-affiliated stockholders entered voting and support agreements to vote covered shares in favor of the merger and against specified competing or obstructive proposals. The filing excerpt does not state the number of shares covered.
- If the merger closes, Lifecore common stock will be delisted from Nasdaq and deregistered under the Exchange Act.
Outlook, risks, and unusual items
The transaction remains proposed and could fail to close or be delayed. Key risks disclosed include failure to obtain stockholder or regulatory approval, termination and possible fees, litigation, transaction costs, restrictions on operations while the deal is pending, management distraction, and effects on employees, customers, vendors, and other relationships. The CVRs are uncertain: Parent is not obligated to achieve the milestones, and the CVR agreement does not impose a fiduciary duty to holders. The specified Alcon agreements must remain in effect as a closing condition.
Most important facts for investors to verify
- Review the definitive proxy statement for the board’s analysis, transaction details, voting requirements, and any fairness materials.
- Confirm the exact treatment of each security class and equity award, including the preferred-stock Conversion Amount and the number and allocation of CVRs.
- Read the full CVR agreement for milestone calculations, partial-payment and catch-up mechanics, litigation adjustments, and limits on transfer.
- Track stockholder approval, HSR and other regulatory clearances, the status of the Alcon agreements, and the expected closing timeline.
- Assess the financing commitments and closing conditions, and monitor any competing proposals, litigation, or changes to the merger agreement.
- Consult Lifecore’s other SEC filings for current financial results, debt, liquidity, operating risks, and information not included in this transaction-focused 8-K.